secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001193125-24-248755
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics appoints Arun Swaminathan as CEO, Howard Berman becomes Executive Chairman effective Nov 1, 2024
--------------------------------------------------------------------------------

- Swaminathan employment agreement provides $525,000 base salary, eligible for annual bonus up to 50% of base.
- Berman employment agreement provides $420,000 base salary, eligible for annual bonus up to 50% of base.
- Swaminathan becomes CEO on Nov 1, 2024; Berman resigns as CEO on Oct 31, 2024, remains on Board as Executive Chairman.
- Severance: if terminated without cause, 12 months base salary continuation plus prorated bonus for each.
- Non-compete for Swaminathan: 6 months post-termination, restricted to IL-2, CTLA-4 Ig, exosome product companies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/0001193125-24-248755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524248755/d840498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-248755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer